H.ZhangJ.LinJ.LiH.LiY
"Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach"
BPC-157, TB-500, and growth hormone-releasing peptides like CJC-1295 are all prohibited by WADA and can be detected with specialized tests
Formulation: 5mg oral capsule, 30-count Dosing: 1 capsule daily, taken in the morning Supply: 30-day supply Best for: All new patients, daily cognitive support, brain fog, memory improvement, focus optimization 3-month commitment: $265/month ($795 total) Formulation: 25mg oral capsule, 30-count Dosing: 1 capsule daily or intermittent schedule as prescribed Supply: 30-day supply Best for: Patients with demonstrated tolerance on 5mg seeking accelerated cognitive enhancement, provider-directed higher-dose protocols 3-month commitment: $575/month ($1,725 total) Both formulations include your clinical consultation, pharmaceutical-grade compounded Dihexa from a licensed pharmacy, and ongoing provider access for dosing adjustments and monitoring

Community protocols on TRT describe: BPC-157: 250-500 mcg subcutaneous, 1-2x daily (near the injury site when possible) TB-500: 2-5 mg subcutaneous, 2x per week (loading), then 2 mg weekly (maintenance) Stacking both for 4-8 weeks for injury recovery No cycling described used as needed during recovery periods For the detailed breakdown, see our BPC-157 dosing guide, TB-500 dosing guide, and the BPC-157 vs TB-500 comparison